🌅 Today's Morning Call
|
S&P Futures
7,512.00
▲ +12.75 (+0.17%)
|
Nasdaq Futures
28,669.75
▲ +56.25 (+0.20%)
|
Dow Futures
52,702.00
▲ +275.00 (+0.52%)
|
|
10Y Treasury
4.68%
▼ -0.02%
|
US Dollar
101.37
▲ +0.16 (+0.16%)
|
Bitcoin
$65,173
▼ -$164 (-0.25%)
|
Data as of 8:08 AM ET
Good morning! It's Monday, July 27, 2026, and futures are pointing higher across the board as the week kicks off with a mix of biotech drama, a splashy acquisition, and a court victory for Elon Musk's Tesla. The Dow is leading the charge, up over 270 points in pre-market, while the S&P and Nasdaq are tagging along with modest gains. Here's what's on the radar this morning.
👀 What to Watch Today
The biotech space is front and center today after argenx (ARGX) announced it will acquire Forte Biosciences (FBRX) in a deal worth roughly $2.2 billion. The target is FB102, an experimental autoimmune drug that argenx is betting big on. Expect FBRX shares to make a dramatic move at the open, while ARGX investors weigh whether the price tag is worth it.AstraZeneca (AZN) is also in focus after a mixed bag of news. On one hand, the company posted solid revenue growth driven by oncology sales. On the other, its rare disease drug Ultomiris failed a late-stage trial in patients dealing with blood vessel complications following stem cell transplants. That's the kind of one-two punch that keeps AZN holders on their toes.
Keep an eye on TotalEnergies (TTE) as well. The French energy giant said it plans to appeal a court ruling that ordered it to align its business strategy with climate goals. It's a legal and PR story that could move the stock and ripple through the broader energy sector today.
Your Phone Is Smarter Than Your Inbox
Not every market move can wait. Our text alerts deliver the ones that can't. One short alert, straight to your phone, when something is worth seeing now. No fluff. No noise. No charge.
Text Me the Alerts🌏 Overnight Recap
Asian markets traded cautiously overnight with no dramatic swings, while European markets opened on a steady note ahead of the U.S. session. Treasury yields are modestly lower this morning, with the 10-year sitting at 4.68%, which is giving equities a small tailwind as borrowing cost pressure eases slightly at the margin.The dollar index (DXY) ticked up to 101.37, holding firm but not surging, which is a relatively benign backdrop for multinational earnings. Bitcoin slipped just under a quarter percent to $65,173, staying in its recent holding pattern without any major catalyst to break it in either direction.
One headline worth noting from the weekend: Shein dropped its long-awaited Hong Kong IPO filing, revealing a $99 million quarterly loss as U.S. import duty changes on small packages started biting into its business model. It's not a directly tradable U.S. stock yet, but the disclosure adds context for investors watching the broader e-commerce and apparel sector.
Sponsored Content
3 AI stocks to buy before August 2026
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005.
Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.
📊 Pre-Market Movers
FBRX is the obvious name to watch in pre-market after argenx confirmed the $2.2 billion acquisition. Forte Biosciences shareholders are looking at a major premium, and the stock should open sharply higher. ARGX itself may see some give-back as investors process the cost of the deal and what it means for the company's balance sheet near term.AZN is under pressure following the Ultomiris trial failure, even with the revenue growth headline offering some cushion. When a late-stage trial misses its primary endpoint, the market tends to punish first and ask questions later. The oncology strength is a real positive, but one clinical setback can overshadow a lot of good news on a Monday morning.
TSLA is getting some quiet attention after winning its bid to revive a UK lawsuit related to 5G patent licensing ahead of a product launch. It's not a blockbuster mover, but any headline involving Tesla and Elon Musk tends to attract eyeballs. Watch for volume to build as retail traders pick up the story through the morning session.
🔍 Today's Watchlist
- ARGX and FBRX: The $2.2 billion acquisition of Forte Biosciences is the deal of the morning. Watch FBRX for a significant pop and ARGX for potential pressure as the market digests the deal premium.
- AZN earnings and trial data: AstraZeneca is navigating a tricky morning with oncology-driven revenue growth offset by the Ultomiris trial failure. The stock's direction will set the tone for large-cap pharma today.
- TTE legal headlines: TotalEnergies appealing its climate court ruling is a developing story. Watch for analyst commentary and any broader read-through to other European energy names.
- Treasury yields and rate sentiment: The modest dip in yields this morning is a small positive for growth stocks. Any shift in this trend during the session could redirect sector rotation quickly.
- TSLA patent developments: Tesla's London court win to revive its 5G patent license lawsuit against InterDigital is a lower-profile story but worth tracking as it could affect future licensing costs and tech IP narratives.
Sponsored Content
Where I'd put $10,000 today
Whitney Tilson recommended Netflix, Amazon, and Apple before massive gains. Now he says one little-known company sits at the center of the AI boom, the energy crisis, and a major commodity supercycle, controlling minerals so vital the White House invoked emergency powers to protect them.
🎯 The Morning Playbook
The setup for Monday is constructive but not explosive. Futures are green, yields are cooperating, and the dollar is not running away to the upside. The real stories today are stock-specific, which means the index moves may be modest while individual names see significant swings.Biotech is the sector to watch most closely. The ARGX and FBRX deal injects deal premium excitement into the space, while AZN's mixed report reminds investors that clinical trial risk never fully goes away. If you're positioned in pharma or biotech, today is a good day to review your risk levels before the open.
More broadly, this is a week where earnings, macro data, and geopolitical noise will all compete for attention. Starting the week with a clear head and a focused watchlist matters more than chasing every headline. Stay selective, stay patient, and let the market come to you.
📰 Further Reading
SPCX Warning - and Worst News for Stocks in 50 Years (Ad)
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in 50 years - and it has nothing to do with a single stock. According to multiple Wall Street banks, a coming crisis could keep your portfolio in the red for 10 years or longer. Keith Kaplan, C...
Learn how to prepare your portfolio.
Five Big Banks Agree ... $6k Gold is Coming (Ad)
When was the last time JPMorgan, UBS, Deutsche Bank, and Wells Fargo all agreed on the same thing? It almost never happens. JPMorgan sees $6,300 by year-end. UBS says $6,200 by June. Deutsche Bank, Societe Generale, and BNP Paribas all see $6,000 or higher. And with gold's recent dip–roughly 10% ove...
Claim your FREE Gold Bull Run guide (plus bonus report) →
Your book is inside (Ad)
Bill Poulos is offering his "Simple Options Trading For Beginners" book at no cost, but that window will not stay open. He plans to charge for this training in the future, so anyone who grabs a copy now keeps it at no charge, regardless of what it costs later.
Get your Simple Options Trading For Beginners book